NeuroPace, Inc. NPCE

Company Overview

NeuroPace, Inc. is a U.S.-based medical technology company focused on neuromodulation therapies for neurological disorders, primarily drug-resistant epilepsy. The company develops and commercializes implantable medical devices that monitor and respond to abnormal electrical activity in the brain. NeuroPace operates within the broader medical device, neurotechnology, and neuroscience healthcare sectors, with its principal commercial platform centered on responsive neurostimulation therapies for patients whose seizures are not adequately controlled by medication.

The company’s primary revenue driver is the RNS System, an implantable and FDA-approved responsive neurostimulation platform designed to detect and treat seizure activity in real time. NeuroPace primarily serves epilepsy centers, neurosurgeons, neurologists, and patients with focal epilepsy that is resistant to pharmaceutical treatment. The company has positioned itself as a specialized leader in closed-loop brain-responsive neurostimulation, differentiating itself from traditional open-loop stimulation systems through continuous brain monitoring and individualized therapy adjustments. NeuroPace was founded in 1997 and evolved from an early-stage neurotechnology developer into a commercial-stage medical device company following FDA approval of the RNS System in 2013 and its subsequent public listing on Nasdaq under the ticker NPCE.